BioCentury
ARTICLE | Finance

Imago-in' places

Imago reunites FerroKin vets to target gene expression in blood disorders

November 10, 2014 8:00 AM UTC

The team at Imago BioSciences Inc. raised a $26.5 million series A round geared to helping them repeat their performance at hematology play FerroKin BioSciences Inc., this time with compounds that modulate gene expression to treat rare genetic hematologic disorders.

Lead investor Clarus Ventures was joined by Frazier Healthcare, Amgen Ventures and Merck Research Labs Venture Fund. Clarus' Dennis Henner and Frazier's Patrick Heron joined the board...